Cenicriviroc + Atorvastatin = Unknown or no reaction

Effect on Concentration

Cenicriviroc
Unknown
Applies within class?
No
Atorvastatin
Increase
Applies within class?
No

Pharmacologic Effects

Cenicriviroc
Effect
N/A
Applies within class?
No
Atorvastatin
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 20-Jul-2018

Summary

Sources

Cenicriviroc versus Atorvastatin ^

Study Design

This was a phase 1, 3 period fixed-sequence study with n=12 healthy subjects evaluating the effect of cenicriviroc (CVC) dosed at 150mg QD for 10 days on the PK, safety and tolerability of atorvastatin. Subjects received 20mg of atorvastatin on day 1 then CVC alone for 10 days which is started on day 2 or 3 based on atorvastatin half-life and then CVC with atorvastatin on the last day of the study. Plasma concentrations were collected over 24-48 hours post-dose for atorvastatin with or without CVC administration. Other PK parameters were determined using non-compartmental methods. Geometric least squares ratios and confidence intervals were estimated.

Study Results

Based on GMRs and 90% confidence intervals, there was a 37% increase in AUC (1.27, 1.48) and a 22% increase in Cmax (1.02, 1.46) of atorvastatin. PK parameters for CVC were not reported.

Study Conclusions

This combination was generally well tolerated, with no adverse events leading to treatment discontinuation. Per the authors, clinically significant PK interactions between cenicriviroc and atorvastatin are not anticipated.

References

Lefebvre, Harris. Effect of cenicriviroc on the pharmacokinetics and safety of hmg-coa reductase inhibitors (simvastatin, simvastatin and rosuvastatin) in healthy subjects . Aasld: American Association Of The Study Of Liver Diseases. Boston, MA, USA. 2016; November .